Fresenius Medical’s Novalung ECMO System selected by Premier

Fresenius Medical’s (FMS) heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premier in the U.S. Since acquiring Xenios in 2016, Fresenius has been dedicated to advancing heart and lung therapy. The Novalung System for extracorporeal membrane oxygenation – ECMO -, was the first system FDA-cleared for long-term ECMO. The system pumps and oxygenates the blood of patients with acute respiratory failure or acute cardiopulmonary failure. Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings. Premier is a healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare.